The Challenges and the Promise of Molecular Targeted Therapy in Malignant Gliomas
Malignant gliomas are the most common malignant primary brain tumors and one of the most challenging forms of cancers to treat. Despite advances in conventional treatment, the outcome for patients remains almost universally fatal. This poor prognosis is due to therapeutic resistance and tumor recur...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-03-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558615000202 |
id |
doaj-a93065f64f6f44f4ad5f27da460b68a7 |
---|---|
record_format |
Article |
spelling |
doaj-a93065f64f6f44f4ad5f27da460b68a72020-11-24T23:19:01ZengElsevierNeoplasia: An International Journal for Oncology Research1476-55861522-80022015-03-0117323925510.1016/j.neo.2015.02.002The Challenges and the Promise of Molecular Targeted Therapy in Malignant GliomasHongxiang Wang0Tao Xu1Ying Jiang2Hanchong Xu3Yong Yan4Da Fu5Juxiang Chen6Department of Neurosurgery, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, ChinaDepartment of Neurosurgery, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, ChinaDepartment of Neurosurgery, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, ChinaDepartment of Neurosurgery, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, ChinaDepartment of Neurosurgery, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, ChinaInstitute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, ChinaDepartment of Neurosurgery, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China Malignant gliomas are the most common malignant primary brain tumors and one of the most challenging forms of cancers to treat. Despite advances in conventional treatment, the outcome for patients remains almost universally fatal. This poor prognosis is due to therapeutic resistance and tumor recurrence after surgical removal. However, over the past decade, molecular targeted therapy has held the promise of transforming the care of malignant glioma patients. Significant progress in understanding the molecular pathology of gliomagenesis and maintenance of the malignant phenotypes will open opportunities to rationally develop new molecular targeted therapy options. Recently, therapeutic strategies have focused on targeting pro-growth signaling mediated by receptor tyrosine kinase/RAS/phosphatidylinositol 3-kinase pathway, proangiogenic pathways, and several other vital intracellular signaling networks, such as proteasome and histone deacetylase. However, several factors such as cross-talk between the altered pathways, intratumoral molecular heterogeneity, and therapeutic resistance of glioma stem cells (GSCs) have limited the activity of single agents. Efforts are ongoing to study in depth the complex molecular biology of glioma, develop novel regimens targeting GSCs, and identify biomarkers to stratify patients with the individualized molecular targeted therapy. Here, we review the molecular alterations relevant to the pathology of malignant glioma, review current advances in clinical targeted trials, and discuss the challenges, controversies, and future directions of molecular targeted therapy. http://www.sciencedirect.com/science/article/pii/S1476558615000202 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hongxiang Wang Tao Xu Ying Jiang Hanchong Xu Yong Yan Da Fu Juxiang Chen |
spellingShingle |
Hongxiang Wang Tao Xu Ying Jiang Hanchong Xu Yong Yan Da Fu Juxiang Chen The Challenges and the Promise of Molecular Targeted Therapy in Malignant Gliomas Neoplasia: An International Journal for Oncology Research |
author_facet |
Hongxiang Wang Tao Xu Ying Jiang Hanchong Xu Yong Yan Da Fu Juxiang Chen |
author_sort |
Hongxiang Wang |
title |
The Challenges and the Promise of Molecular Targeted Therapy in Malignant Gliomas |
title_short |
The Challenges and the Promise of Molecular Targeted Therapy in Malignant Gliomas |
title_full |
The Challenges and the Promise of Molecular Targeted Therapy in Malignant Gliomas |
title_fullStr |
The Challenges and the Promise of Molecular Targeted Therapy in Malignant Gliomas |
title_full_unstemmed |
The Challenges and the Promise of Molecular Targeted Therapy in Malignant Gliomas |
title_sort |
challenges and the promise of molecular targeted therapy in malignant gliomas |
publisher |
Elsevier |
series |
Neoplasia: An International Journal for Oncology Research |
issn |
1476-5586 1522-8002 |
publishDate |
2015-03-01 |
description |
Malignant gliomas are the most common malignant primary brain tumors and one of the most challenging forms of cancers to treat. Despite advances in conventional treatment, the outcome for patients remains almost universally fatal. This poor prognosis is due to therapeutic resistance and tumor recurrence after surgical removal. However, over the past decade, molecular targeted therapy has held the promise of transforming the care of malignant glioma patients. Significant progress in understanding the molecular pathology of gliomagenesis and maintenance of the malignant phenotypes will open opportunities to rationally develop new molecular targeted therapy options. Recently, therapeutic strategies have focused on targeting pro-growth signaling mediated by receptor tyrosine kinase/RAS/phosphatidylinositol 3-kinase pathway, proangiogenic pathways, and several other vital intracellular signaling networks, such as proteasome and histone deacetylase. However, several factors such as cross-talk between the altered pathways, intratumoral molecular heterogeneity, and therapeutic resistance of glioma stem cells (GSCs) have limited the activity of single agents. Efforts are ongoing to study in depth the complex molecular biology of glioma, develop novel regimens targeting GSCs, and identify biomarkers to stratify patients with the individualized molecular targeted therapy. Here, we review the molecular alterations relevant to the pathology of malignant glioma, review current advances in clinical targeted trials, and discuss the challenges, controversies, and future directions of molecular targeted therapy.
|
url |
http://www.sciencedirect.com/science/article/pii/S1476558615000202 |
work_keys_str_mv |
AT hongxiangwang thechallengesandthepromiseofmoleculartargetedtherapyinmalignantgliomas AT taoxu thechallengesandthepromiseofmoleculartargetedtherapyinmalignantgliomas AT yingjiang thechallengesandthepromiseofmoleculartargetedtherapyinmalignantgliomas AT hanchongxu thechallengesandthepromiseofmoleculartargetedtherapyinmalignantgliomas AT yongyan thechallengesandthepromiseofmoleculartargetedtherapyinmalignantgliomas AT dafu thechallengesandthepromiseofmoleculartargetedtherapyinmalignantgliomas AT juxiangchen thechallengesandthepromiseofmoleculartargetedtherapyinmalignantgliomas AT hongxiangwang challengesandthepromiseofmoleculartargetedtherapyinmalignantgliomas AT taoxu challengesandthepromiseofmoleculartargetedtherapyinmalignantgliomas AT yingjiang challengesandthepromiseofmoleculartargetedtherapyinmalignantgliomas AT hanchongxu challengesandthepromiseofmoleculartargetedtherapyinmalignantgliomas AT yongyan challengesandthepromiseofmoleculartargetedtherapyinmalignantgliomas AT dafu challengesandthepromiseofmoleculartargetedtherapyinmalignantgliomas AT juxiangchen challengesandthepromiseofmoleculartargetedtherapyinmalignantgliomas |
_version_ |
1725578969461293056 |